CT与FDG PET-CT检测复发性胰腺癌诊断性能的系统评价与Meta分析
该系统评价与Meta分析纳入7项回顾性研究共333例相关患者,评估CT与FDG PET-CT检测胰腺导管腺癌切除术后复发的诊断性能。CT汇总敏感度0.70、特异度0.80;FDG PET-CT汇总敏感度0.88、特异度0.89;FDG PET-CT联合增强CT汇总敏感度0.95、特异度0.81。作者认为术后CT诊断准确性中等,当CT阴性或可疑而临床怀疑复发时FDG PET-CT可能具附加价值,但支持影像学监测的证据有限,需前瞻性研究优化监测策略。
要点
- CT检测复发的汇总敏感度0.70(95%CI 0.61-0.78)、特异度0.80(95%CI 0.69-0.88)。
- FDG PET-CT汇总敏感度0.88(95%CI 0.81-0.93)、特异度0.89(95%CI 0.80-0.94)。
- FDG PET-CT联合增强CT汇总敏感度0.95(95%CI 0.88-0.98)、特异度0.81(95%CI 0.63-0.92)。
核心结论
- 依据当前文献,术后CT检测复发性胰腺癌的诊断准确性为中等;当CT阴性或结果可疑而仍怀疑复发时,FDG PET-CT可能具有附加价值;但支持PDAC切除术后影像学监测的证据有限,未来需前瞻性研究以优化胰腺癌切除术后的监测策略。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE和Cochrane Library至2017年12月20日。
关键影像表现/征象
- 7项回顾性研究共333例相关患者纳入数据提取,全部7篇报道增强CT的检查结果。
- 5篇报道FDG PET-CT的诊断准确性结果,3篇报道FDG PET-CT联合增强CT的诊断准确性结果。
- 采用QUADAS-2工具评价方法学质量,纳入研究的总体方法学质量可接受。
- 采用双变量随机效应模型计算敏感度和特异度的汇总估计值,诊断准确性数据以森林图呈现。
诊断标准与关键数值
- CT检测复发的汇总敏感度0.70(95%CI 0.61-0.78),汇总特异度0.80(95%CI 0.69-0.88)。
- FDG PET-CT检测复发的汇总敏感度0.88(95%CI 0.81-0.93),汇总特异度0.89(95%CI 0.80-0.94)。
- FDG PET-CT联合增强CT检测复发的汇总敏感度0.95(95%CI 0.88-0.98),汇总特异度0.81(95%CI 0.63-0.92)。
- 参考标准为复发性PDAC的组织学确认或随访影像显示疾病进展的临床确认。
临床应用与阅片要点
- 作者认为,当CT阴性或结果可疑而仍怀疑复发时,FDG PET-CT可能具有附加价值。
- 作者指出,支持PDAC切除术后影像学监测的证据有限。
- 作者提出,未来需前瞻性研究以优化胰腺癌切除术后的监测策略。
局限性
- 纳入的7项研究均为回顾性研究(原文:seven retrospective studies)。
- 支持PDAC切除术后影像学监测的证据有限(原文:evidence supporting radiologic surveillance after resection of PDAC is limited)。
- 未来需前瞻性研究以优化胰腺癌切除术后的监测策略(原文:Future prospective studies are needed)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Radiologic surveillance after resection of pancreatic ductal adenocarcinoma (PDAC) can provide information on the extent and location of disease recurrence. This systematic review and meta-analysis aims to give an overview of the literature on the diagnostic performance of different imaging modalities for the detection of recurrent disease after surgery for PDAC.
METHODS: A systematic search was performed in PubMed, EMBASE and Cochrane Library up to 20 December 2017. All studies reporting on the diagnostic value of imaging modalities for the detection of local and/or distant disease recurrence during follow-up after resection of PDAC were eligible. Both histologic confirmation of recurrent PDAC and clinical confirmation by disease progression on follow-up imaging were considered as suitable reference standard. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was used for critical appraisal of methodological quality. Diagnostic accuracy data were extracted or calculated and presented in forest plots. A bivariate random-effects model was used to calculate pooled estimates of sensitivity and specificity.
RESULTS: A total of seven retrospective studies with 333 relevant patients were ultimately eligible for data extraction. Overall, the methodological quality of the included studies was acceptable. All seven articles described test results of contrast-enhanced CT, whilst five and three articles reported outcomes on diagnostic accuracy of FDG PET-CT and FDG PET-CT combined with contrast-enhanced CT, respectively. For CT, pooled estimates for sensitivity were 0.70 (95% CI 0.61-0.78) and for specificity 0.80 (95% CI 0.69-0.88). For FDG PET-CT, pooled estimates for sensitivity and specificity were 0.88 (95% CI 0.81-0.93) and 0.89 (95% CI 0.80-0.94), respectively. For FDG PET-CT in combination with contrast-enhanced CT, pooled estimates for sensitivity were 0.95 (95% CI 0.88-0.98) and for specificity 0.81 (95% CI 0.63-0.92).
CONCLUSIONS: According to the current literature, post-operative CT has a moderate diagnostic accuracy in the detection of recurrent disease. FDG PET-CT imaging could be of additional value when disease recurrence is suspected despite negative or equivocal CT findings. Nevertheless, evidence supporting radiologic surveillance after resection of PDAC is limited. Future prospective studies are needed to optimize surveillance strategies after resection of pancreatic cancer.
引用
- Daamen LA, Groot VP, Goense L, et al. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Eur J Radiol. 2018. PMID: 30150034. doi:10.1016/j.ejrad.2018.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。